Rigel has an exclusive license and supply agreement with Medison to commercialize TAVALISSE (fostamatinib) in all potential indications in Canada and Israel.
TAVALISSE launched in Canada in December 2020 for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments.
TAVALISSE launched in Israel in November 2022 for the treatment of chronic ITP in adult patients who are refractory to other treatments.
Rigel received an upfront payment, which included an advanced royalty payment, is eligible for regulatory and commercial milestone payments, and receives tiered royalty payments on net sales of TAVALISSE in the territory.